Syros Pharmaceuticals (SYRS) News Today $0.27 -0.02 (-5.66%) (As of 02:09 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Syros Pharmaceuticals Faces Default on $43.6 Million Loan After Key Clinical Trial FailureOn November 12, 2024, Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) found itself in a challenging position as an event of default transpired under the Loan and SecuNovember 19 at 4:39 AM | americanbankingnews.comSyros Pharmaceuticals Faces Financial Struggles Amid Key ChallengesNovember 18 at 5:44 PM | markets.businessinsider.comHC Wainwright Has Bearish Forecast for SYRS FY2026 EarningsNovember 18 at 4:05 AM | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $5.00 Consensus Target Price from AnalystsNovember 18 at 2:45 AM | americanbankingnews.comSyros Pharmaceuticals' (SYRS) Neutral Rating Reaffirmed at HC WainwrightNovember 17, 2024 | americanbankingnews.comSyros Pharmaceuticals' (SYRS) Hold Rating Reaffirmed at TD CowenNovember 17, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for SYRS Q1 EarningsNovember 16, 2024 | americanbankingnews.comSyros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRSNovember 15, 2024 | markets.businessinsider.comSyros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setbackNovember 15, 2024 | investing.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock, Short Interest ReportNovember 14, 2024 | benzinga.comJMP Securities downgrades Syros Pharmaceuticals (SYRS) to a HoldNovember 14, 2024 | markets.businessinsider.comSyros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan DefaultNovember 14, 2024 | benzinga.comSyros Pharmaceuticals downgraded to Neutral from Buy at H.C. WainwrightNovember 14, 2024 | finance.yahoo.comTD Cowen Downgrades Syros Pharmaceuticals (SYRS)November 14, 2024 | msn.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of "Buy" by BrokeragesShares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) have received an average rating of "Buy" from the three analysts that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a buy rating. The average 12 month target price amoNovember 13, 2024 | marketbeat.comTD Cowen Reiterates "Hold" Rating for Syros Pharmaceuticals (NASDAQ:SYRS)TD Cowen reaffirmed a "hold" rating on shares of Syros Pharmaceuticals in a research note on Wednesday.November 13, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Earns "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating and set a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday.November 13, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Earns "Market Perform" Rating from JMP SecuritiesJMP Securities reissued a "market perform" rating on shares of Syros Pharmaceuticals in a report on Wednesday.November 13, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Receives Hold Rating from Brookline Capital ManagementBrookline Capital Management reissued a "hold" rating on shares of Syros Pharmaceuticals in a report on Wednesday.November 13, 2024 | marketbeat.comSyros Pharmaceuticals trading halted, news pendingNovember 13, 2024 | markets.businessinsider.comSyros Pharmaceuticals (SYRS) was downgraded to a Hold Rating at TD CowenNovember 13, 2024 | markets.businessinsider.comSyros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene OverexpressionNovember 12, 2024 | businesswire.comSyros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.comStockNews.com downgraded Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday.November 4, 2024 | marketbeat.comSyros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)November 4, 2024 | finance.yahoo.comSyros Pharmaceuticals: Promising Breakthrough with Tamibarotene in High-Risk MDSNovember 1, 2024 | markets.businessinsider.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comSyros Pharmaceuticals (NASDAQ:SYRS) Announces Earnings ResultsSyros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) released its earnings results on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period last year, the firm posted ($1.35) EPS.November 1, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $6.00 price target on shares of Syros Pharmaceuticals in a research report on Friday.November 1, 2024 | marketbeat.comSyros Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 1, 2024 | finance.yahoo.comSyros Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comSyros Pharmaceuticals, Inc.November 1, 2024 | cnn.comSyros Pharmaceuticals: Promising Prospects with Strong Cash Position and Advancing Phase 3 Trial in HR-MDSNovember 1, 2024 | markets.businessinsider.comSyros Pharmaceuticals (SYRS) Set to Announce Earnings on ThursdaySyros Pharmaceuticals (NASDAQ:SYRS) will be releasing earnings before the market opens on Thursday, October 31, Zacks reports.October 25, 2024 | marketbeat.comSyros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law FirmOctober 24, 2024 | stockhouse.comSyros Pharmaceuticals (NASDAQ:SYRS) Rating Increased to Hold at StockNews.comStockNews.com raised Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Tuesday.October 15, 2024 | marketbeat.comSyros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...October 9, 2024 | finance.yahoo.comSyros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.comStockNews.com cut Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday.October 7, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock Price Crosses Below Fifty Day Moving Average of $2.91Syros Pharmaceuticals (NASDAQ:SYRS) Share Price Crosses Below 50-Day Moving Average of $2.91October 2, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 25, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 17, 2024 | prnewswire.comInsider Spends US$161k Buying More Shares In Syros PharmaceuticalsSeptember 15, 2024 | sg.finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) CFO Buys $54,812.65 in StockSeptember 13, 2024 | insidertrades.comInsider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)September 12, 2024 | finance.yahoo.comInsider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)September 12, 2024 | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 9, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 3, 2024 | prnewswire.comSyros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for AllegedSeptember 3, 2024 | prnewswire.comIndividuals With Losses In Syros Pharmaceuticals Inc. Should Join The Schall Law Firm In An Inquiry Into Possible Securities Law ViolationsAugust 30, 2024 | stockhouse.comSyros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged WrongdoingsAugust 30, 2024 | globenewswire.comSyros Pharmaceuticals to Present at Upcoming Medical and Investor ConferencesAugust 27, 2024 | finance.yahoo.com Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] SYRS Media Mentions By Week SYRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRS News Sentiment▼-0.040.47▲Average Medical News Sentiment SYRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRS Articles This Week▼203▲SYRS Articles Average Week Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRZN News KALA News DARE News HCWB News TNXP News BLRX News INKT News ATHA News MRKR News LPCN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
